0001493152-26-022792
SEC filingMicrobot Medical’s Q1 FY2026 marks its commercial debut with $105K in revenue from the LIBERTY® Endovascular Robotic System’s Limited Market Release, but operating losses widened to -$4.3M amid scaled commercialization investments and minimal gross profit.
Microbot Medical reported $105K in revenue for Q1 FY2026 — its first recorded commercial revenue — entirely attributable to the Limited Market Release of the LIBERTY® Endovascular Robotic System, which commenced in Q3 2025 and continued through March 31, 2026. As stated in Management Discussion, this release targeted 'select high procedure volume regions' to validate clinical utility and early customer adoption. The revenue is not indicative of near-term scale but serves as an inflection point confirming transition from R&D to commercial execution.
Gross profit totaled $2.0K, resulting in a 1.9% gross margin. This narrow margin stems from low production volumes, third-party manufacturing costs, and initial inventory ramp-up — all inherent to early commercial deployment. Critically, management explicitly states: 'We expect our gross margin to increase over the long term with production scale and other planned manufacturing efficiencies.' This framing confirms the current margin is transitional and not reflective of underlying product economics at scale.
Operating income declined to -$4.3M (from -$3.0M in Q1 FY2025), a 43.0% YoY deterioration. Per Management Discussion, this increase in operating loss was 'primarily due to an increase in payroll and related expenses mainly due to new hiring, salary increases and bonuses and increase in commercialization activities.' These investments align with the company’s stated intent to build out marketing and sales teams for the LIBERTY® system, alongside legal, accounting, insurance, and investor relations expenses required for public company compliance.
Net cash used in operating activities was -$5.1M (vs. -$2.9M in Q1 FY2025), underscoring the capital intensity of commercial preparation ahead of full market release. Capital expenditures rose to $108K (from $13K year-ago), supporting infrastructure for U.S. commercial readiness — including office leases and operational systems — consistent with management’s commentary on expanding commercialization activities. Free cash flow totaled -$5.2M, reflecting the combined impact of operating outflows and growth-related investments.
The Company continues to anticipate raising additional capital through debt or equity issuances and potential grants from the Israeli Innovation Authority. There is no revision to management’s long-term outlook: SG&A expenses are expected to increase over time, gross margin is expected to improve with scale, and commercial expansion remains central to the strategy — all directly supported by statements in the business context packet.